AnaptysBio, Inc. (ANAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANAB POWR Grades
- Growth is the dimension where ANAB ranks best; there it ranks ahead of 77.27% of US stocks.
- ANAB's strongest trending metric is Growth; it's been moving up over the last 178 days.
- ANAB's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).
ANAB Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for ANAB is 0.04 -- better than merely 11.06% of US stocks.
- With a price/sales ratio of 59.19, ANAPTYSBIO INC has a higher such ratio than 96.75% of stocks in our set.
- Revenue growth over the past 12 months for ANAPTYSBIO INC comes in at -83.72%, a number that bests just 1.67% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ANAPTYSBIO INC, a group of peers worth examining would be ICVX, CUE, MRTX, INDI, and AEVA.
- ANAB's SEC filings can be seen here. And to visit ANAPTYSBIO INC's official web site, go to www.anaptysbio.com.
ANAB Valuation Summary
- In comparison to the median Healthcare stock, ANAB's price/earnings ratio is 120.8% lower, now standing at -4.7.
- Over the past 75 months, ANAB's price/earnings ratio has gone up 67.8.
Below are key valuation metrics over time for ANAB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ANAB | 2023-03-17 | 59.2 | 2.3 | -4.7 | -4.3 |
| ANAB | 2023-03-16 | 60.0 | 2.4 | -4.8 | -4.4 |
| ANAB | 2023-03-15 | 62.4 | 2.4 | -5.0 | -4.6 |
| ANAB | 2023-03-14 | 62.1 | 2.4 | -5.0 | -4.6 |
| ANAB | 2023-03-13 | 61.3 | 2.4 | -4.9 | -4.5 |
| ANAB | 2023-03-10 | 60.7 | 2.4 | -4.9 | -4.5 |
ANAB Growth Metrics
- Its 4 year price growth rate is now at -23.75%.
- Its 5 year net cashflow from operations growth rate is now at -658.91%.
- Its year over year cash and equivalents growth rate is now at -41.45%.
The table below shows ANAB's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 4.49 | -88.209 | -134.849 |
| 2022-06-30 | 24.087 | -77.468 | -108.013 |
| 2022-03-31 | 52.898 | -43.73 | -75.888 |
| 2021-12-31 | 63.175 | -45.92 | -57.796 |
| 2021-09-30 | 122.164 | 16.959 | 8.388 |
| 2021-06-30 | 101.274 | 6.952 | -8.713 |
ANAB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ANAB has a Quality Grade of C, ranking ahead of 73.88% of graded US stocks.
- ANAB's asset turnover comes in at 0.294 -- ranking 156th of 682 Pharmaceutical Products stocks.
- AUPH, OCX, and LFVN are the stocks whose asset turnover ratios are most correlated with ANAB.
The table below shows ANAB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.294 | 1 | 0.079 |
| 2021-06-30 | 0.249 | 1 | -0.071 |
| 2021-03-31 | 0.178 | 1 | -0.215 |
| 2020-12-31 | 0.184 | 1 | -0.115 |
| 2020-09-30 | 0.044 | 1 | -0.376 |
| 2020-06-30 | 0.042 | 1 | -0.370 |
ANAB Price Target
For more insight on analysts targets of ANAB, see our ANAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $35.33 | Average Broker Recommendation | 1.79 (Moderate Buy) |
ANAB Stock Price Chart Interactive Chart >
ANAB Price/Volume Stats
| Current price | $21.76 | 52-week high | $32.44 |
| Prev. close | $21.62 | 52-week low | $18.20 |
| Day low | $21.28 | Volume | 197,400 |
| Day high | $22.52 | Avg. volume | 336,444 |
| 50-day MA | $24.44 | Dividend yield | N/A |
| 200-day MA | $25.13 | Market Cap | 607.78M |
AnaptysBio, Inc. (ANAB) Company Bio
AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.
Latest ANAB News From Around the Web
Below are the latest news stories about ANAPTYSBIO INC that investors may wish to consider to help them evaluate ANAB as an investment opportunity.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue EstimatesAnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateInitiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic dermatitis anticipated Q2 2023Initiating second Phase 2 trial for rosnilimab in an indication to be announced anticipated year-end 2023Filing IND for ANB033 (anti-CD122 antagonist) anticipated H1 2024Top-line data from the GEMINI-1 Phase 3 trial for imsidolimab (anti-IL-36R antagonist) to treat GPP anticipat |
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care ConferenceSAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m. ET / 11:50 a.m. PT. A live audio webcast of the presentation will be available on the investor section of the AnaptysBio website at http |
AnaptysBio Announces Stock Repurchase PlanSAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and investments greater than $575 million as of December 31, 2022, notwithstanding the |
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating AntibodiesAdvancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023Advancing rosnilimab into a second Phase 2 trial, in an indication to be announced, with study initiation anticipated by year-end 2023Blinded interim review of alopecia areata Phase 2a data demonstrated rosnilimab “proof of mechanism” with robus |
ANAB Price Returns
| 1-mo | N/A |
| 3-mo | -25.84% |
| 6-mo | -14.36% |
| 1-year | -13.48% |
| 3-year | 64.23% |
| 5-year | -80.30% |
| YTD | -29.78% |
| 2022 | -10.82% |
| 2021 | 61.63% |
| 2020 | 32.31% |
| 2019 | -74.53% |
| 2018 | -36.67% |
Continue Researching ANAB
Here are a few links from around the web to help you further your research on Anaptysbio Inc's stock as an investment opportunity:Anaptysbio Inc (ANAB) Stock Price | Nasdaq
Anaptysbio Inc (ANAB) Stock Quote, History and News - Yahoo Finance
Anaptysbio Inc (ANAB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...